- 专利标题： COMPOSITION OF NY-ESO-1-SPECIFIC T CELL RECEPTORS RESTRICTED ON MULTIPLE MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULES
-
申请号： US17273192申请日： 2019-09-04
-
公开(公告)号： US20210324035A1公开(公告)日： 2021-10-21
- 发明人: Owen N. Witte , Jami McLaughlin Witte , Antoni Ribas , Lili Yang , Michael T. Bethune , Jonathan Cebon , Katherine Woods , Ashley J. Knights , David Baltimore
- 申请人： The Regents of the University of California , California Institute of Technology , The Olivia Newton-John Cancer Research Institute
- 申请人地址： US CA Oakland; US CA Pasadena; AU Victoria
- 专利权人： The Regents of the University of California,California Institute of Technology,The Olivia Newton-John Cancer Research Institute
- 当前专利权人： The Regents of the University of California,California Institute of Technology,The Olivia Newton-John Cancer Research Institute
- 当前专利权人地址： US CA Oakland; US CA Pasadena; AU Victoria
- 国际申请： PCT/US19/49484 WO 20190904
- 主分类号： C07K14/725
- IPC分类号： C07K14/725 ; A61K35/17 ; C12N15/86 ; C12N5/0783 ; A61P35/00
摘要：
Tumor-specific T cell receptor (TCR) gene transfer enables specific and potent immune targeting of tumor antigens. The canonical cancer-testis antigen, NY-ESO-1, is not expressed in normal tissues but is aberrantly expressed across a broad array of cancer types. It has also been targeted with A2-restricted TCR gene therapy without adverse events or notable side effects. To enable the targeting of NY-ESO-1 in a broader array of HLA haplotypes, we isolated TCRs specific for NY-ESO-1 epitopes presented by four MHC molecules: HLA-A2, -B07, -B18, and -C03. Using these TCRs, we have developed an approach to extend TCR gene therapies targeting NY-ESO-1 to patient populations beyond those expressing HLA-A2.